BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression
August 29, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights
August 10, 2022 07:30 ET
|
BrainsWay
Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd....
BrainsWay to Report Second Quarter Financial Results on August 10, 2022
July 27, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression
June 28, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for...
BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference
June 22, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™
June 21, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 21, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights
May 11, 2022 07:30 ET
|
BrainsWay
Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd....
BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales
May 09, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, May 09, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society
May 04, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, May 04, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month
May 02, 2022 08:46 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive...